Pharmaceutical Solutions

Transcu Group Limited ("Transcu" or collectively with its subsidiaries, "the Group") focuses on the research & development of Transdermal Drug Delivery Technologies ("T-DDS") and seeks to deploy the proprietary T-DDS devices for pharmaceutical and cosmeceutical applications. Transcu's technology comprises an active iontophoresis T-DDS and an Ionic Passive® T-DDS. The active iontophoresis T-DDS uses an external electrical power source to deliver ionised drugs through the skin effectively and painlessly. The electrical source produces gentle electric current that controls the rate and duration of drug delivery. The Ionic Passive® T-DDS, on the other hand, utilises a simple, relatively inexpensive and optimised enhancer patch system to deliver ionised drugs through the skin without the use of an external power source.

The benefits of T-DDS are:

• Non-invasive method which reduces pain associated with injections;
• Systematic delivery of drugs through the skin which eliminates gastrointestinal side effects from oral administration of drugs and bypasses the first pass metabolism in liver;
• Innovative, simple and pain-free delivery that improves patient compliance to medication; and
• User-friendly design suitable for potential home administration.

To develop its pharmaceutical business, Transcu employs a two-pronged business approach namely, a joint development strategy and an independent development strategy.

Joint Development

Transcu will partner with pharmaceutical companies worldwide to develop new drug-device products incorporating their patented drugs with our proprietary T-DDS technology. These pharmaceutical companies will collaborate under a license arrangement with Transcu to jointly develop new drug-device products that will eventually be sold commercially.

Independent Development

Transcu will either partner with generic pharmaceutical companies to collaborate and develop new generic drugdevice products incorporating off-patent drugs with our proprietary T-DDS technology or partially develop these generic drug device products by seeking funding from investors. These new generic drug-device products will be marketed by generic pharmaceutical companies or distribution partners.